Research programme: gastrointestinal disorder therapeutics - Beacon Discovery/Takeda
Latest Information Update: 28 Mar 2022
At a glance
- Originator Beacon Discovery; Takeda
- Class Small molecules
- Mechanism of Action G protein-coupled receptor modulators
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Gastrointestinal disorders
Most Recent Events
- 28 Mar 2022 No recent reports of development identified for research development in Gastrointestinal-disorders in Japan
- 28 Mar 2022 No recent reports of development identified for research development in Gastrointestinal-disorders in USA
- 27 Feb 2018 Beacon Discovery signs a research collaboration agreement with Takeda for development of therapeutics for Gastrointestinal disorders